Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 8
1994 1
1995 4
1996 8
1997 8
1998 13
1999 22
2000 27
2001 37
2002 29
2003 34
2004 43
2005 26
2006 34
2007 30
2008 41
2009 28
2010 26
2011 25
2012 26
2013 20
2014 9
2015 16
2016 18
2017 7
2018 12
2019 16
2020 9
2021 13
2022 11
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Trial: Diurnal IOP Fluctuations in Glaucoma Using Latanoprost and Timolol with Self-Tonometry.
Tong J, Huang J, Kalloniatis M, Coroneo M, Zangerl B. Tong J, et al. Optom Vis Sci. 2021 Aug 1;98(8):901-913. doi: 10.1097/OPX.0000000000001751. Optom Vis Sci. 2021. PMID: 34393206 Clinical Trial.
PURPOSE: This study aimed to investigate fluctuations in diurnal IOP measurements in patients with open-angle glaucoma and ocular hypertension treated with latanoprost 0.005% and timolol 0.25%. METHODS: In this crossover treatment trial, 14 participants performed self-tono …
PURPOSE: This study aimed to investigate fluctuations in diurnal IOP measurements in patients with open-angle glaucoma and ocular hypertensi …
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. Aihara M, et al. Am J Ophthalmol. 2020 Dec;220:53-63. doi: 10.1016/j.ajo.2020.06.003. Epub 2020 Jun 10. Am J Ophthalmol. 2020. PMID: 32533949 Free article. Clinical Trial.
At baseline, patients who received OMDI or latanoprost had a mean SD diurnal IOP of 23.78 1.73 mm Hg and 23.40 1.51 mm Hg, respectively. At week 4, least-squares mean SE reduction in IOP from baseline with OMDI (-5.93 0.23 mm Hg) was noninferior to that of latanoprost
At baseline, patients who received OMDI or latanoprost had a mean SD diurnal IOP of 23.78 1.73 mm Hg and 23.40 1.51 mm Hg, respective …
Prospective randomized clinical trial on the effects of latanoprost, travoprost and bimatoprost on latanoprost non-responders.
Blondeau P, Hamid M, Ghalie Z. Blondeau P, et al. J Fr Ophtalmol. 2019 Oct;42(8):894-899. doi: 10.1016/j.jfo.2019.02.009. Epub 2019 Jun 1. J Fr Ophtalmol. 2019. PMID: 31164290 Clinical Trial.
PURPOSE: To determine whether a patient who is non-responder to latanoprost after one month of use should continue using latanoprost or switch to either bimatoprost or travoprost. ...Before latanoprost treatment, the mean intraocular pressure was 23.74.7mmHg. …
PURPOSE: To determine whether a patient who is non-responder to latanoprost after one month of use should continue using latanopro
Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial.
Ghassemi M, Yazdanian N, Behrangi E, Jafari M, Goodarzi A. Ghassemi M, et al. Dermatol Ther. 2022 Dec;35(12):e15943. doi: 10.1111/dth.15943. Epub 2022 Oct 25. Dermatol Ther. 2022. PMID: 36257912 Clinical Trial.
Alopecia areata (AA), a polygenic and chronic autoimmune disease and there is no definitive cure. We aimed to evaluate latanoprost effects in patients with AA. In this controlled randomized double-blind clinical trial, we enrolled patients with AA randomly assigned to six …
Alopecia areata (AA), a polygenic and chronic autoimmune disease and there is no definitive cure. We aimed to evaluate latanoprost ef …
A Non-Inferiority Study of Combination of Latanoprost and Timolol Formulation to Their Separate Use in Drug-Naive Primary Open Angle Glaucoma and Ocular Hypertension Nigerian Patients. {RCT 93803536 (Nigeria Clinical Trial Registry)}.
Abikoye OP, Abesin OO, Onabolu OO, Ajibode HA, Adepoju FG, Musibau RO. Abikoye OP, et al. West Afr J Med. 2023 Dec 31;40(12):1285-1290. West Afr J Med. 2023. PMID: 38259047 Clinical Trial.
AIM: This study aimed to demonstrate the non-inferiority of a fixed combination of front-line drugs in the medical management of glaucoma (latanoprost and timolol) compared to concomitant use of the same drugs. ...CONCLUSION: The study was able to demonstrate a noninferior …
AIM: This study aimed to demonstrate the non-inferiority of a fixed combination of front-line drugs in the medical management of glaucoma ( …
Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
Wisely CE, Sheng H, Heah T, Kim T. Wisely CE, et al. Adv Ther. 2020 Mar;37(3):1114-1123. doi: 10.1007/s12325-020-01227-y. Epub 2020 Jan 24. Adv Ther. 2020. PMID: 31981106 Free PMC article. Clinical Trial.
INTRODUCTION: To describe the changes in endothelial cell density (ECD), the coefficient of variation (CV), the percentage of hexagonal cells (%HEX), and central corneal thickness (CCT) following 3 months of therapy with netarsudil 0.02%/latanoprost 0.005% fixed combinatio …
INTRODUCTION: To describe the changes in endothelial cell density (ECD), the coefficient of variation (CV), the percentage of hexagonal cell …
Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure.
Jampel HD, Bacharach J, Sheu WP, Wohl LG, Solish AM, Christie W; Latanoprost/Unoprostone Study Group. Jampel HD, et al. Am J Ophthalmol. 2002 Dec;134(6):863-71. doi: 10.1016/s0002-9394(02)01820-2. Am J Ophthalmol. 2002. PMID: 12470755 Clinical Trial.
PURPOSE: To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension. ...No serious adverse event related to either med …
PURPOSE: To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprosto …
Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial.
Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L, Sunaric-Mégevand G, Rossetti L. Stalmans I, et al. Graefes Arch Clin Exp Ophthalmol. 2016 Jun;254(6):1151-8. doi: 10.1007/s00417-016-3299-9. Epub 2016 Feb 24. Graefes Arch Clin Exp Ophthalmol. 2016. PMID: 26907933 Clinical Trial.
PURPOSE: The aim of this study was to investigate the efficacy and safety of Bimatoprost Unit Dose Preservative Free (BUDPF) and Latanoprost Unit Dose Preservative Free (LUDPF). METHODS: A prospective, randomized, investigator-masked, cross-over comparison was used. ...
PURPOSE: The aim of this study was to investigate the efficacy and safety of Bimatoprost Unit Dose Preservative Free (BUDPF) and Latanopr
A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma.
Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. Dirks MS, et al. Adv Ther. 2006 May-Jun;23(3):385-94. doi: 10.1007/BF02850159. Adv Ther. 2006. PMID: 16912020 Clinical Trial.
After washout of all ocular hypotensive medications, patients with normal-tension glaucoma (n=60) were randomly assigned to oncedaily bimatoprost 0.03% or latanoprost 0.005% for 3 mo. Diurnal IOP measurements were taken at each study visit. ...After 3 mo of treatment, mean …
After washout of all ocular hypotensive medications, patients with normal-tension glaucoma (n=60) were randomly assigned to oncedaily bimato …
Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial.
Lee NY, Park HY, Park CK. Lee NY, et al. PLoS One. 2016 Jan 12;11(1):e0146680. doi: 10.1371/journal.pone.0146680. eCollection 2016. PLoS One. 2016. PMID: 26756747 Free PMC article. Clinical Trial.
Patients in group A were treated with DTFC, lubricant, and latanoprost for 4 weeks each, whereas patients in group B were treated with latanoprost, lubricant, and DTFC for 4 weeks each. ...CONCLUSIONS: IOP lowering efficacy of DTFC was noninferior to that of lata
Patients in group A were treated with DTFC, lubricant, and latanoprost for 4 weeks each, whereas patients in group B were treated wit …
560 results